HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125

Benzinga Newsdesk www.benzinga.com Positive 78.3%

Neg 0% Neu 0% Pos 78.3%

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $105 to $125.